The company said that based on the encouraging study results of the pivotal phase 2 conducted by Biocon in India, its US-based partner, Equilllium, is planning to conduct a global randomized controlled clinical trial of Itolizumab in Covid-19 patients for which it will file a US investigational new drug application (IND) soon.
from The Financial Express https://ift.tt/30PxoiA
Monday, 27 July 2020
Biocon to submit more data on Itolizumab to Covid taskforce
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment